一种新型长效肼屈嗪类血管扩张剂ISF 2469与β受体阻滞剂及利尿剂联合使用的降压疗效。 - Suppr

Suppr

超能文献

Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.

作者信息

van Brummelen P, Bühler F R, Kiowski W, Bolli P, Bertel O

出版信息

Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):380-5.

PMID:40887

Abstract

摘要

相似文献

Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.一种新型长效肼屈嗪类血管扩张剂ISF 2469与β受体阻滞剂及利尿剂联合使用的降压疗效。

Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):380-5.

[Treatment of severe arterial hypertension with propyldazine (ISF 2123) associated with a diuretic and a beta-blocking agent].用丙酰肼（ISF 2123）联合利尿剂和β受体阻滞剂治疗重度动脉高血压

Minerva Cardioangiol. 1979 Mar;27(3):113-8.

Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.卡屈嗪，一种新型血管扩张剂，与β受体阻滞剂联合用于高血压的长期治疗。

Arzneimittelforschung. 1985;35(3):623-5.

[Beta blockaders in the treatment of hypertension. Part 2. Antihypertensive effect: hypotheses on the mechanism of action and practical methods of treatment].[β受体阻滞剂治疗高血压。第2部分。降压效果：作用机制假说及实际治疗方法]

Coeur Med Interne. 1978 Jul-Sep;17(3):381-400.

Therapy with hydrazinopyridazine, a new antihypertensive vasodilatory agent, in combination with beta-receptor blocking substances.用新型抗高血压血管扩张剂肼屈嗪与β受体阻滞剂联合进行治疗。

Int J Clin Pharmacol Ther Toxicol. 1980;18(5):233-5.

Pharmacological basis for combination therapy of hypertension.高血压联合治疗的药理学基础。

Annu Rev Pharmacol Toxicol. 1977;17:311-23. doi: 10.1146/annurev.pa.17.040177.001523.

A preliminary clinical trial of Prazosin: a new oral antihypertensive agent.哌唑嗪初步临床试验：一种新型口服抗高血压药物。

N Z Med J. 1974 May 22;79(516):969-72.

Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.原发性高血压中的β-肾上腺素能受体阻滞与血管舒张。静息及应激状态下的血流动力学研究。

Acta Med Scand Suppl. 1984;689:1-46.

Current trends in the management of hypertension.高血压管理的当前趋势

Compr Ther. 1980 Mar;6(3):23-28.

Hypertension in the elderly: treatment.老年人高血压：治疗

Cardiol Clin. 1986 May;4(2):245-52.

引用本文的文献

Studies on the metabolism of cadralazine in rat.

Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):39-45. doi: 10.1007/BF03189541.

[14C]cadralazine: absorption, distribution and excretion in rat and dog.[14C]卡屈嗪：在大鼠和犬体内的吸收、分布及排泄

Eur J Drug Metab Pharmacokinet. 1983;8(1):25-33. doi: 10.1007/BF03189578.

Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.卡屈嗪（ISF 2469）：单次口服给药后对患者产生与剂量相关的降压活性。

Eur J Clin Pharmacol. 1983;24(2):157-61. doi: 10.1007/BF00613810.

Human pharmacokinetics of cadralazine: a new vasodilator.

Eur J Drug Metab Pharmacokinet. 1985 Jul-Sep;10(3):217-23. doi: 10.1007/BF03189745.

Disposition and pharmacokinetics of cadralazine and individual metabolites in man.卡屈嗪及其个别代谢产物在人体中的处置与药代动力学。

Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):147-53. doi: 10.1007/BF03189709.

Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.卡屈嗪和氯噻酮作为阿替洛尔的第二步用药用于高血压患者：运动期间血压控制的差异

Eur J Clin Pharmacol. 1986;30(2):145-50. doi: 10.1007/BF00614292.

Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.卡屈嗪对预先使用β受体阻滞剂和利尿剂治疗的患者的急性全身和肾脏血流动力学影响及长期降压作用。

Eur J Clin Pharmacol. 1987;31(5):513-8. doi: 10.1007/BF00606622.

Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.卡屈嗪。对其药效学和药代动力学特性以及在高血压治疗中的治疗潜力的综述。

Drugs. 1990 Oct;40(4):543-60. doi: 10.2165/00003495-199040040-00005.

Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.

Eur J Clin Pharmacol. 1991;40(5):461-5. doi: 10.1007/BF00315223.

Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.卡屈嗪及其肼基代谢产物在肾功能损害患者中每日一次重复给予5mg后的药代动力学。

Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):213-20. doi: 10.1007/BF03190148.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验